PAYS
Paysign, Inc.5.45
+0.09+1.68%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Reaffirms momentum, GLP-1 upside
Q&A largely reaffirmed prepared remarks' upbeat tone on patient affordability, with Turner countering slowdown fears by citing bulging pharma pipelines and Lilly's deal frenzy. Management revealed positioning for a GLP-1 diabetes program win within 12-18 months, while plasma growth stems from comping prior lows and 10% collection efficiencies. They sized pharma TAM at $500M-$850M—first inning—and touted moats like 97% dynamic rules efficacy and payments insights. Analysts probed GLP-1s, competition, and worries; answers were direct, confident, zero red flags. Dynamic rules crush retail volumes. Watch Q1 program ramp to 137.
Key Stats
Market Cap
299.98MP/E (TTM)
41.92Basic EPS (TTM)
0.13Dividend Yield
0%Recent Filings
10-K
FY2025 results
Paysign crushed FY2025 ended December 31, 2025 with revenues leaping 40.5% to $82.0M, fueled by pharma's 167.8% surge to $33.9M from 55 net new programs and plasma's steady 4.0% rise to $45.6M despite 115 net center adds amid softer loads. Gross margins expanded to 59.4% on higher-margin pharma mix, driving operating income up 621% to $7.4M while Q4 momentum built through program ramps and $1.94B gross dollar volume (8.5% y/y). Gamma acquisition closed March 2025; $3M remains in buyback authorization. Unrestricted cash hit $21.1M. Data breaches threaten cardholder trust.
8-K
40% revenue growth, pharma surges
Paysign crushed 2025 with revenues soaring 40.5% to $82.0M, fueled by pharma jumping 167.8% from 55 new patient programs while plasma grew 4.0% across 595 centers. Net income doubled to $7.55M; balance sheet shines with $21.1M unrestricted cash, zero debt. Guides 2026 revenue to $106.5M-$110.5M. Pharma now drives margins.
10-Q
Q3 FY2025 results
Paysign crushed Q3 with revenues jumping 41.6% y/y to $21.6M, fueled by pharma surging 141.9% y/y from 39 new programs while plasma grew 12.4% y/y on 117 net centers. Gross margin edged to 56.3%; operating income more than doubled to $1.6M as pharma's higher margins offset amortization from Gamma acquisition (closed March 2025 for $15.6M cash/stock/contingent, $4.5M goodwill, $11.1M intangibles over 9-15 years). Diluted EPS held at $0.04 despite dilution; cash fell to $7.5M after $4.4M operating cash flow. Stock repurchases continue. Pharma claims processed up 60% y/y. Donor management tech bolsters plasma retention. Derivative suits pending final approval.
8-K
Q3 revenues up 41.6%
Paysign crushed Q3 2025 with revenues soaring 41.6% to $21.6 million, fueled by pharma patient affordability jumping 141.9% to $7.92 million across 105 programs. Net income climbed 54.2% to $2.22 million; Adjusted EBITDA rocketed 78.1% to $5.04 million (23.3% margin, reconciled). Plasma grew 12.4% to $12.86 million despite softer per-center revenue. Momentum builds, but plasma faces inventory oversupply.
8-K
Paysign settles derivative suits
Paysign settled derivative lawsuits alleging fiduciary breaches from 2019-2020 IT control failures and misleading disclosures, which delayed its 10-K filing. The deal mandates five-year corporate governance reforms, including new IT and disclosure committees, auditor rotation, and enhanced whistleblower policies, while insurers cover $607,500 in plaintiffs' fees. Reforms promise stronger oversight. Litigation ends November 14, 2025.
IPO
Website
Employees
Sector
Industry
CPAY
Corpay, Inc.
312.42+0.26
IPSI
Innovative Payment Solutions, I
0.01+0.00
PAGS
PagSeguro Digital Ltd.
9.71-0.31
PAY
Paymentus Holdings, Inc.
30.76+0.52
PAYC
Paycom Software, Inc.
162.77-0.04
PAYD
Paid, Inc.
3.29+0.00
PAYO
Payoneer Global Inc.
5.89+0.07
PSFE
Paysafe Limited
8.14-0.04
RPAY
Repay Holdings Corporation
3.69+0.29
SMKG
Smart Card Marketing Systems, I
0.00+0.00